Trasylol Heart Attack Lawsuit

FDA Recalls Trasylol - Cites Increased Heart Attacks and Strokes

On November 5, 2007, the FDA recalls Trasylol from the market due to seriously increased risks of heart attacks, strokes, kidney damage and kidney failure (see FDA Trasylol Recall). The FDA recall of Trasylol stems from Dr. Dennis Mangano's latest findings, in which he concluded that 22,000 cardiac patients could have been saved if Trasylol had been taken off the market in January 2006 when his Trasylol side effects study was first published. Dr. Dennis Mangano's study found that Trasylol increased the risk of Trasylol-related heart attacks, Trasylol-related strokes, Trayslol-related kidney damage, kidney failure, and death in heart bypass patients. It is estimated that Trasylol damages costs over $1 billion in health care every year. Most heart surgery patients don't know if they were given Trasylol during their open heart surgery until an investigation into their records is conducted after a Trasylol heart attack or stroke side effect is discovered.

Bayer's Failure to Disclose Increased Trasylol Heart Attack Data to FDA

On September 21, 2006 the FDA's Cardiovascular and Renal Drug Advisory Committee met to evaluate current data regarding Trasylol side effects. On September 29, 2006, the FDA issued a public health advisory stating that it had new information that Bayer failed to disclose an earlier study that it had conducted involving 67,000 heart surgery patients. Preliminary review of this study suggested that Trasylol side effects included higher risks for stroke, congestive heart failure, kidney damage, and death. Bayer failed to disclose the existence of the Trasylol study during the Advisory Committee on September 21, 2006 and continued to market Trasylol for use in cardiac procedures knowing about increased risks of Trasylol heart attacks and strokes.

Risks of a Trasylol Heart Attack

A Trasylol heart attack is an injury caused by lack of blood supply to the heart muscle. Heart attacks, which have been proven to be a considerable risk with Trasylol, can destroy parts of the heart muscle causing potentially fatal harm to the patient. In the Trasylol study by Dr. Dennis T. Mangano it was determined that the risk of experiencing a Trasylol heart attack may be increased by as much as 50 percent in comparison to other medications. The study to establish the risk for Trasylol heart attacks and other adverse side effects examined over 4,000 heart surgery patients who were given either Trasylol, alternative medications or no medication at all. This Trasylol medical study is very disturbing especially since 1000's of Trasylol heart attacks and kidney failures have been taking place almost unchecked for 13 years without the intervention of the FDA or a mandated FDA recall of Trasylol.

Trasylol Heart Attack Lawsuit

If you or a loved one has suffered a heart attack, stroke, kidney damage, or kidney failure after a cardiac catherization, a heart bypass surgery or any other cardiac operation, then call our offices to discuss your legal rights to a possible Trasylol heart attack lawsuit. Talk to a Board Certified Personal Injury Trial Lawyer and get your questions answered. Contact our law firm today.